ARA-290

ARA-290 is the compound in this reference most deserving of more trials and least able to get them. The science worked. The clinical evidence is real. The company that owned it is gone. And the people who need it most are left with gray-market research chemicals and a Phase 2 dataset that demonstrated exactly what they're looking for.

The central tension resolved: ARA-290 was engineered specifically to not be EPO. It has no erythropoietic effects — confirmed in every human trial. It does not raise red blood cells. It does not improve athletic performance through hematological mechanisms. Its clinical evidence is for neuropathy, nerve regeneration, and inflammatory conditions — nothing about performance enhancement. WADA banned it anyway under S2, because the IRR it activates includes an EPO receptor subunit. The compound cannot get a Phase 3 trial because its developer ran out of money. And it sits in a strange liminal space: better controlled human evidence than almost any other compound in the longevity/research space for its specific indication, inaccessible through any approved clinical channel, available only from research chemical vendors, banned for athletes who cannot benefit from its actual mechanism, and used by a small community of people with actual nerve damage who have run out of conventional options.

The strongest argument for ARA-290: the Phase 2 corneal nerve fiber density finding is the most objectively meaningful piece of human clinical data in the neuropathy/nerve regeneration space. No approved compound has demonstrated measurable small fiber nerve regeneration in a controlled trial. ARA-290 did it, in 40 patients, measured by confocal microscopy, in a randomized double-blind trial at an independent academic institution. The mechanism is precisely characterized and biologically elegant. The safety profile across all trials is excellent. The dosing protocol derived from the successful Phase 2 trial is directly available to community users. The community's most common use case — intractable neuropathic pain — is precisely the population the clinical data was generated in.

The strongest argument for caution: Phase 2 is Phase 2. No Phase 3 data. The evidence base is real but small (40 patients in the pivotal trial). No pharmaceutical oversight, no approved clinical access, no regulatory framework for the community's use. WADA ban is a career-ending risk for any competitive athlete. Active malignancy contraindication based on theoretical mechanism. Long-term immunogenicity uncharacterized. And the compound has no commercial steward who might advance it further.